| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Iora Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $400.14M | Series F | 2/10/2020 | $150M | $790.13M | $9.49 | Premji Invest, Cox Enterprises, Temasek, Devonshire Investors, .406 Ventures, Flare Capital Partners, Polaris Partners, Khosla Venture | ||||
 | Livongo | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $237.65M | Series E | 4/23/2018 | $105M | $796.49M | $8.30 | General Catalyst, KinnevikMerck, Global Health Innovation Fund, Wanxiang America, M12, Echo Health Ventures, Sapphire Ventures, Zaffre Investments, 7wire Ventures, Kleiner Perkins and Draper Fisher Jurvetson Management | ||||
 | Superluminal Medicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $218.16M | Series B-1 | 9/3/2026 | $60M | $600.4M | $3.28 | BVF Partners, Deep Track Capital, Perceptive Advisors, RA Capital Management, Insight Partners, NVIDIA, Catalio Capital Management, Eli Lilly and Company, Cooley, Gaingels | ||||
 | Welltok | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $516.04M | Series E-4NV | 10/16/2020 | $28M | $981.31M | $11.44 | TriZetto, Sillicon Valley Bank, Grupo SURA | ||||
 | Collate | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $125.5M | Series A | 6/3/2026 | $95M | $724.46M | $43.78 | Redpoint, First Round Capital, Conviction Partners, Y Combinator | ||||
 | InterVenn | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $245.77M | Series C | 8/2/2021 | $201.27M | $685.15M | $8.83 | A.G. Hill Partners, Amplify Partners, Anzu Partners, Genoa Ventures, Heritage Provider Network, Highside Capital Management, Irving Investors, Softbank Group, True Ventures | ||||
 | Mercator MedSystems | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $68.55M | Series 1 | 3/4/2021 | $58.37M | $694.21M | $20.00 | Undisclosed Investors | ||||
 | R-Zero | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $173.45M | Series C | 2/16/2023 | $105M | $526.86M | $14.13 | BMO Financial Group, Qualcomm Ventures, Upfront Ventures, DBL Partners, World Innovation Lab, Mayo Clinic, Bedrock Capital, SOSV, John Doerr | ||||
 | UpStream | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $185M | Series B | 10/6/2022 | $120M | $781.85M | $2.71 | Coatue, Dragoneer Investment Group, Avidity Partners, Define Ventures, Mubadala | ||||
 | Alumis | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.66B | Series C | 3/6/2024 | $259M | $702.67M | $3.14 | Foresite Capital, Samsara BioCapital, venBio Partners, Cormorant Asset Management, SR One, Lilly Asia Ventures, Nextech, Ally Bridge Group, HBM Healthcare Investments, Omega Funds, Piper Heartland Healthcare, AyurMaya Capital Management | ||||
 | MapLight Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $511M | Series D | 9/30/2025 | $200M | $883.21M | $0.95 | Catalyst4, Forbion, Sanofi, Novo Holdings | ||||
 | PROCEPT BioRobotics | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $341.8M | Series G | 6/30/2021 | $85M | $872.62M | $4.02 | Fidelity, T. Rowe Price Associates, CPMG, Perceptive Advisors, Viking Global Investors LP, Duquesne Family Office | ||||
 | Saliogen Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $156.22M | Series B | 1/5/2022 | $132.25M | $549.61M | $105.86 | GordonMD Global Investments, EPIQ Capital Group, Fidelity, T. Rowe Price, D1 Capital Partners, SymBiosis, Cystic Fibrosis Foundation, RD Fund | ||||
 | Vividion Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $267.82M | Series C | 2/24/2021 | $135M | $600.09M | $2.10 | Logos Capital, Boxer Capital, SoftBank, Avoro Capital Advisors, BlackRock, RA Capital Management, T. Rowe Price Associates, Surveyor Capital, Woodline Partners, Acuta Capital, Driehaus Capital Management, ARCH Venture Partners, BVF Partners, Casdin Capital, Mubadala Capital, Nextech Invest, Versant Ventures | ||||
 | Quartet Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $279.11M | Series B | 12/10/2021 | $60M | $646.74M | $11.26 | Independence, GV, Oak HC/FT | ||||
 | Truepill | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $929.28M | Series E-1 | 8/16/2023 | $7.49M | $541.17M | $22.68 | Undisclosed Investors | ||||
 | Gelesis | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $207.14M | Series Growth 3 | 7/19/2020 | $100.49M | $801M | $17.27 | Vitruvian Partners, Hambro Perks | ||||
 | Pathway Genomics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $127.23M | Series E-1 | 1/5/2016 | $40M | $932.69M | $9.50 | International Business Machines | ||||
 | Omega Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $202.49M | Series C | 3/3/2021 | $125.5M | $504.38M | $11.33 | Flagship Pioneering, Invus, Fidelity, BlackRock, Cowen Healthcare Investments, Point72, Logos Capital, Mirae Asset Capital | ||||
 | Dyno Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $111M | Series A | 5/6/2021 | $100M | $539.27M | $44.66 | Andreessen Horowitz, Casdin Capital, GV, Obvious Ventures, Lux Capital | ||||